Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darin K Edwards

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Current Opinion in Immunology|June 7, 2022
Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospectsDarin K Edwards, Andrea Carfi
Cell|March 19, 2021
Novel approaches for vaccine developmentMakda S Gebre, Luis A Brito, Lisa H Tostanoski, et al.
Journal of Translational Medicine|January 5, 2017
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate responseDarin K Edwards, Edith Jasny, Heesik Yoon, et al.
Journal of Virology|August 28, 2024
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strainBaoling Ying, Chieh-Yu Liang, Pritesh Desai, et al.
Vaccine|February 25, 2026
Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 VaccinesWoo Yun Sohn, Susan M G Goody, David W Reid, et al.
Journal of Virology|September 22, 2021
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 VariantsAngela Choi, Matthew Koch, Kai Wu, et al.
Medrxiv : the Preprint Server for Health Sciences|March 16, 2022
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Spyros Chalkias, Howard Schwartz, Biliana Nestorova, et al.
Nature Microbiology|April 3, 2023
Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2Samantha R Mackin, Pritesh Desai, Bradley M Whitener, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2022
Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2Samantha R Mackin, Pritesh Desai, Bradley M Whitener, et al.
Open Forum Infectious Diseases|December 4, 2025
Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult ParticipantsAmparo L Figueroa, Bethany Girard, Darin K Edwards, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Current Opinion in Immunology|June 7, 2022
Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospectsDarin K Edwards, Andrea Carfi
Cell|March 19, 2021
Novel approaches for vaccine developmentMakda S Gebre, Luis A Brito, Lisa H Tostanoski, et al.
Journal of Translational Medicine|January 5, 2017
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate responseDarin K Edwards, Edith Jasny, Heesik Yoon, et al.
Journal of Virology|August 28, 2024
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strainBaoling Ying, Chieh-Yu Liang, Pritesh Desai, et al.
Vaccine|February 25, 2026
Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 VaccinesWoo Yun Sohn, Susan M G Goody, David W Reid, et al.
Journal of Virology|September 22, 2021
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 VariantsAngela Choi, Matthew Koch, Kai Wu, et al.
Medrxiv : the Preprint Server for Health Sciences|March 16, 2022
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Spyros Chalkias, Howard Schwartz, Biliana Nestorova, et al.
Nature Microbiology|April 3, 2023
Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2Samantha R Mackin, Pritesh Desai, Bradley M Whitener, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2022
Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2Samantha R Mackin, Pritesh Desai, Bradley M Whitener, et al.
Open Forum Infectious Diseases|December 4, 2025
Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult ParticipantsAmparo L Figueroa, Bethany Girard, Darin K Edwards, et al.
Pageof 6